Articles related to DRUG SAFETY & INTERACTIONS

Updated infectious diseases guidance addresses resistant gram-negative infections through pathogen-specific treatment pathways, incorporating newer antibiotics and pharmacologic considerations while acknowledging that several preferred approaches rest on limited clinical outcomes data.

The FDA warned that counterfeit over-the-counter eye drops found in several states may contain bacterial contamination capable of causing serious ocular infections. No associated adverse events had been reported when the warning was issued.

A review identified 15 reports of Wernicke encephalopathy among patients receiving GLP-1 therapies, most accompanied by poor intake, vomiting, weight loss, or malnutrition, highlighting a rare safety signal without establishing drug-related causality.

First-trimester benzodiazepine exposure was not associated with a meaningful increase in major congenital malformations in a large US cohort study, although findings related to coexposure with other psychoactive medications remained inconsistent and require further investigation.

In an adaptive randomized trial of adults with long COVID, fluvoxamine modestly reduced fatigue and improved quality-of-life scores through 90 days, while metformin findings remained inconclusive after dose modification and early termination.

The FDA classified a recall of thyroid tablets USP 30 mg as Class I after identification of a superpotent product lot. The recall affects 1,955 bottles and carries risk of serious adverse health consequences, making prompt inventory review and product removal necessary.